SMZ1.STU Sino Biopharmaceutical Limited
- Market cap
- -
- P/E
- 27.4x
- P/B
- 2.28x
- ROE
- 7.6%
- Dividend yield
- 4.55%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is SMZ1.STU undervalued?
Graham numberThe Graham number of Sino Biopharmaceutical Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sino Biopharmaceutical Limited fundamental analysis
No fundamental analysis for Sino Biopharmaceutical Limited yet.
Sino Biopharmaceutical Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited, an investment holding company, researches and develops, produces, and sells Chinese and chemical medicines in Hong Kong, Mainland China, and internationally. The company operates in three segments: Chemical Medicines and Biopharmaceutical Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Runzhong dispersible tablets, Tianqingganmei injections, Tianding tablets, Tianqingganping enteric capsules, Ming…
Full company profileSino Biopharmaceutical Limited financial statements
Sino Biopharmaceutical Limited annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 14.2B | 14.8B | 20.9B | 24.2B | 23.6B | 26.9B | 26.0B | 26.2B | 28.9B | 31.8B |
| Gross Profit | 11.2B | 11.7B | 16.7B | 19.3B | 18.5B | 21.5B | 21.5B | 21.2B | 23.5B | 26.1B |
| Operating Income | 2.89B | 3.27B | 4.57B | 5.25B | 4.30B | 4.35B | 5.48B | 6.09B | 6.33B | 6.90B |
| EBITDA | - | 4.62B | 12.8B | 7.28B | 6.99B | 19.9B | 6.69B | 6.98B | 6.89B | 8.43B |
| Net Income | 1.71B | 2.17B | 9.05B | 2.71B | 2.77B | 14.6B | 2.54B | 2.33B | 3.50B | 2.34B |
| EPS | - | 0.13 | 0.48 | 0.14 | 0.15 | 0.78 | 0.14 | 0.13 | 0.20 | 0.13 |
| Balance Sheet | ||||||||||
| Total Assets | 18.4B | 20.9B | 49.8B | 58.3B | 47.2B | 60.5B | 64.1B | 63.6B | 65.4B | 76.0B |
| Total Liabilities | 7.70B | 8.32B | 12.2B | 18.0B | 24.8B | 22.8B | 26.1B | 25.4B | 22.6B | 33.9B |
| Shareholders' Equity | 7.96B | 9.21B | 29.2B | 31.1B | 16.7B | 30.3B | 29.7B | 30.5B | 32.0B | 30.7B |
| Cash & Short-term Investments | 3.76B | 4.19B | 6.68B | 11.9B | 11.3B | 10.6B | 12.1B | 9.45B | 9.57B | 12.2B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 2.99B | 3.73B | 5.09B | 5.32B | 5.33B | 5.37B | 6.27B | 6.07B | 6.62B | 9.29B |
| Capital Expenditure | 779M | 1.06B | 1.55B | 1.73B | 1.86B | 1.89B | 1.71B | 1.70B | 1.39B | 1.70B |
| Free Cash Flow | - | 2.27B | 3.40B | 3.59B | 3.47B | 3.47B | 4.56B | 4.36B | 5.22B | 7.59B |
| Ratios | ||||||||||
| ROE | 21.5% | 23.6% | 31.0% | 8.7% | 16.5% | 48.2% | 8.6% | 7.7% | 11.0% | 7.6% |
| ROA | 9.3% | 10.4% | 18.2% | 4.6% | 5.9% | 24.1% | 4.0% | 3.7% | 5.4% | 3.1% |
| Net Profit Margin | 12.1% | 14.6% | 43.3% | 11.2% | 11.7% | 54.4% | 9.8% | 8.9% | 12.1% | 7.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sino Biopharmaceutical Limited dividends
- Dividend yield
- 4.55%
- Forward dividend
- -
- Payout ratio
- 64.1%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.50B | 0.08 | 64.1% |
| 2024 | CNY 1.85B | 0.10 | 52.8% |
| 2023 | CNY 633M | 0.03 | 27.1% |
| 2022 | CNY 1.27B | 0.07 | 49.8% |
| 2021 | CNY 938M | 0.05 | 6.4% |
| 2020 | CNY 1.19B | 0.06 | 42.8% |
| 2019 | CNY 820M | 0.04 | 30.3% |
| 2018 | EUR 710M | 0.04 | 7.9% |
| 2017 | EUR 450M | 0.03 | 20.7% |
| 2016 | EUR 376M | - | 21.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:2 on Jul 20, 2020.
Who owns Sino Biopharmaceutical Limited
Ownership data of Sino Biopharmaceutical Limited is not available yet.
Sino Biopharmaceutical Limited company profile
- Company name
- Sino Biopharmaceutical Limited
- Ticker
- SMZ1.STU
- ISIN
- KYG8167W1380
- Exchange
- Stuttgart Exchange
- Sector
- Other
- Industry
- Metals & Mining
- Employees
- 21,302
- Fiscal year end
- December
- Address
- Website
- -
About Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited, an investment holding company, researches and develops, produces, and sells Chinese and chemical medicines in Hong Kong, Mainland China, and internationally. The company operates in three segments: Chemical Medicines and Biopharmaceutical Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Runzhong dispersible tablets, Tianqingganmei injections, Tianding tablets, Tianqingganping enteric capsules, Mingzheng capsules, and Ganze entecavir capsules; cardio-cerebral medicines comprising Kaishi injections, Yilunping and Tuotuo tablets, Kaina tablets, and Tianqingning injections; and oncology medicines consisting of Saiweijian, Tianqingyitai, Qingweike, and Zhiruo injections, as well as Focus V and Genike capsules, and Shoufu and Yinishu tablets. The company's principal products also comprise Analgesic medicines, such as Kaifen injections and Debaian Cataplasms; Orthopedic medicines, which include Gaisanchun capsules and Jiuli tablets; digestive system medicines, such as Aisuping injections and Getai tablets; anti-infectious medicines consisting of Tiance injections and Tianjie tablets; respiratory system medicines, including Tianqingsule inhalation powder and Chia Tai Suke tablets; and parenteral nutritious medicines, such as Xinhaineng and Fenghaineng fructose injections. In addition, it is involved in the development of medicines for tumor, liver, cardio-cerebral, analgesia, respiratory system, and orthopedic diseases; property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management and healthy information services; and outpatient and surgical procedure. Further, the company manufactures, sells, and distributes health food; and develops medical technology. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.